Timmerman Report
The Timmerman Report is a subscription-based publication that operates independently, delivering timely and comprehensive news and analysis in the biotech sector. It caters to anyone interested in gaining insights into the latest developments in drug creation, diagnostics, genomics, and other medical technologies that are reshaping healthcare. My aim is to uncover true innovations, spot emerging trends, and highlight the key players and market dynamics at play. With over ten years of experience covering the industry—including navigating through two downturns and one and a half growth periods—I provide context to stories that few others can offer. Readers can expect a broad perspective along with a consistent flow of news, in-depth features, and original insights. This thorough reporting can equip you for important meetings, help you find collaborators, seize investment opportunities, recruit promising talent, build relationships with colleagues, or even secure a job. I strive to write in a way that is accessible to everyone: offering insights that specialized readers will appreciate while also being understandable for those who are new to the topic. It’s the kind of clear, insightful journalism that remains relevant and valuable over time.
Outlet metrics
Global
#1970670
United States
#669597
Health/Biotechnology and Pharmaceuticals
#574
Articles
-
3 weeks ago |
timmermanreport.com | Luke Timmerman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
-
3 weeks ago |
timmermanreport.com | Luke Timmerman
Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy causes — including cancer research, sickle cell disease and fighting poverty. Here’s how to get involved. Timmerman Traverse for Life Science CaresThis 2-day expedition will be in the North Cascades of Washington state Aug. 17-20, 2025.
-
3 weeks ago |
timmermanreport.com | David Shaywitz |Luke Timmerman
This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness. One result: a randomized controlled study of exercise in 889 cancer patients published in the New England Journal of Medicine (NEJM), and accompanied by a torrent of enthusiastic coverage in the popular press. Another: the publication of two important and thoughtful commentaries about this study, analyses that are the focus of today’s column.
-
4 weeks ago |
timmermanreport.com | Luke Timmerman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.
-
1 month ago |
timmermanreport.com | Luke Timmerman
Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There are people with a mutation of the gene who have considerably lower levels of triglycerides and remnant cholesterol.
Timmerman Report journalists
Contact details
Address
123 Example Street
City, Country 12345
Website
http://timmermanreport.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →